Biomerica AI Stock Analysis
Want to see BMRA full AI Analyst Report?
Biomerica (BMRA) AI Stock Analysis
Biomerica
(NASDAQ:BMRA)
The score is primarily driven by very weak fundamentals (persistent losses, extremely thin margins, and ongoing cash burn) and bearish technicals (price below key moving averages with negative MACD). A small offset comes from the recent financing that supports near-term liquidity, but valuation remains constrained by loss-making operations and the absence of dividend support.
Biomerica (BMRA) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $5.68M
- Dividend Yield
- ―
- Average Volume (3M)
- 72.97K
- Price to Earnings (P/E)
- -0.8
- Beta (1Y)
- 2.03
- Revenue Growth
- -11.20%
- EPS Growth
- -6.64%
- Country
- US
- Employees
- 50
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Devices
Biomerica Business Overview & Revenue Model
Company Description
Biomerica, Inc. is a biomedical technology firm that invents, secures intellectual property for, produces, and globally distributes diagnostic and therapeutic solutions aimed at identifying and addressing a range of medical conditions and diseases. T...
How the Company Makes Money
Biomerica makes money primarily by selling its diagnostic products and related consumables to customers such as clinical laboratories, hospitals/clinics, and distributors. Revenue is generally generated from (1) product sales of test kits and assays...
Biomerica Financial Statement Overview
Summary
Financial performance is weak: revenue contracted sharply and remains low, gross margin is extremely thin, and the company continues to post deep operating and net losses. Cash flow is consistently negative (operating cash flow and free cash flow), implying ongoing funding needs, while leverage has increased despite still-positive equity.
Income Statement
12Very NegativeBalance Sheet
42NeutralCash Flow
18Very Negative| Breakdown | TTM | Aug 2026 | May 2025 | May 2024 | May 2023 | May 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.45M | 4.45M | 5.31M | 5.42M | 5.34M | 18.87M |
| Gross Profit | 360.00K | 362.00K | 498.00K | 611.00K | 446.00K | 2.98M |
| EBITDA | -3.73M | -4.90M | -4.57M | -5.56M | -6.74M | -3.94M |
| Net Income | -3.77M | -3.77M | -4.97M | -5.98M | -7.14M | -4.53M |
Balance Sheet | ||||||
| Total Assets | 6.76M | 6.76M | 5.95M | 9.25M | 14.45M | 11.37M |
| Cash, Cash Equivalents and Short-Term Investments | 1.31M | 1.31M | 2.40M | 4.17M | 9.72M | 5.92M |
| Total Debt | 1.88M | 2.38M | 458.00K | 785.00K | 1.08M | 1.38M |
| Total Liabilities | 4.13M | 4.13M | 1.84M | 2.66M | 2.73M | 3.05M |
| Stockholders Equity | 2.63M | 2.63M | 4.11M | 6.59M | 11.72M | 8.32M |
Cash Flow | ||||||
| Free Cash Flow | -3.46M | -3.42M | -3.88M | -5.48M | -5.55M | -650.87K |
| Operating Cash Flow | -3.42M | -3.42M | -3.84M | -5.36M | -5.47M | -480.53K |
| Investing Cash Flow | -1,000 | -1,000 | -37.00K | -115.00K | -78.00K | -170.34K |
| Financing Cash Flow | 2.33M | 2.33M | 2.11M | -81.00K | 9.39M | 2.39M |
Biomerica Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BMRA, the sentiment is Negative. The current price of 1.24 is below the 20-day moving average (MA) of 1.59, below the 50-day MA of 1.94, and below the 200-day MA of 1.99, indicating a bearish trend. The MACD of -0.16 indicates Positive momentum. The RSI at 24.11 is Positive, neither overbought nor oversold. The STOCH value of 18.94 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BMRA.
Biomerica Risk Analysis
Biomerica disclosed 33 risk factors in its most recent earnings report. Biomerica reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksBiomerica Peers Comparison
Overall Rating
HSCS45Neutral
SSKN43Neutral
PAVM42Neutral
BMRA42Neutral
AMIX40Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 45Neutral | $10.24M | -0.64 | -816.25% | ― | -27.70% | 61.44% | |
| 43Neutral | $589 | 0.00 | -268.41% | ― | -8.54% | 40.91% | |
| 42Neutral | $12.07M | -0.16 | -58.07% | ― | 410.34% | -185.92% | |
| 42Neutral | $5.68M | -0.79 | -142.81% | ― | -11.20% | -6.64% | |
| 40Underperform | $2.21M | -0.05 | -191.88% | ― | ― | 81.59% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| BMRA | Biomerica Inc | 1.24 | -1.01 | -44.87% | |
| SSKN | Strata Skin Sciences | 0.09 | -1.22 | -93.13% | |
| PAVM | Pavmed | 1.51 | -9.18 | -85.87% | |
| HSCS | Heart Test Laboratories, Inc. | 2.06 | -0.85 | -29.21% | |
| AMIX | Autonomix Medical, Inc. | 1.08 | -19.87 | -94.85% |
Biomerica Corporate Events
Biomerica Announces Board and Governance Committee Transition
NeutralOn October 12, 2026, Biomerica, Inc. disclosed that director David Moatazedi will not stand for re-election at the company’s 2026 Annual Meeting of Stockholders, scheduled for December 11, 2026. Moatazedi, who joined the Board in December 2022, curre...
Biomerica Completes Private Placement of Equity Securities
PositiveOn August 20, 2026, Biomerica entered into a securities purchase agreement with institutional and individual investors, including B. Riley Principal Capital and certain directors and executives, to sell 1,393,705 common shares at $1.60 each, raising...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 18, 2026
